Strides Pharma Science
Strides Pharma Science is a publicly listed Indian pharmaceutical company that develops, manufactures, and commercializes IP-led generic formulations across 100+ countries, serving regulated markets, donor-funded public health programs, and African branded generics through seven global manufacturing facilities.
- Company typePublic
- Founded1990
- HeadquartersBangalore, India
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Strides Pharma Science does
Strides Pharma Science Limited, founded in 1990 and headquartered in Bengaluru, is a publicly listed Indian pharmaceutical company (NSE: STAR) that develops, manufactures, and commercializes IP-led niche generic formulations across oral solids, modified-release dosages, topicals, nasal sprays, hormones, and controlled substances. The company operates seven state-of-the-art manufacturing facilities across India, the United States, Italy, and Kenya, with combined annual capacity exceeding 16 billion dosage units, and holds approvals from USFDA, MHRA, TGA, WHO, ANVISA, and other major regulators. It commercializes over 1,000 formulations reaching more than 100 countries.
The company operates four integrated business lines: (1) a regulated-markets generics franchise (US, Canada, Australia, New Zealand, UK, Nordics, DACH) anchored by Strides Pharma Inc. and Strides Pharma International AG; (2) a donor-funded institutional business supplying WHO-prequalified and PEPFAR-approved formulations for HIV/AIDS, malaria, tuberculosis, and hepatitis to Global Fund, USAID, UNICEF, PAHO, UNITAID, and PEPFAR; (3) the Brands Africa branded-generics platform covering 40+ African countries; and (4) specialty/differentiated generics and co-development partnerships (e.g., with Kenox Pharmaceuticals on nasal sprays). UCL Kenya functions as an extended WHO-prequalified manufacturing arm for African and donor-funded programs.
In FY26, Strides reported consolidated revenue of approximately Rs 4,858.68 crore (~$580 million), up 6.43% year-over-year, with a three-year CAGR of approximately 12%. EBITDA margins expanded 400 basis points to 19%, and net debt-to-EBITDA improved from 1.9x to 1.55x. The company has been actively reshaping its portfolio through the demerger and separate listing of OneSource Specialty Pharma (CDMO, January 2025), the sale of an 80.05% stake in Pivot Path to Ascent Capital for Rs 100 crore (June 2026), and the $12 million acquisition of Sandoz's branded generics portfolio for Sub-Saharan Africa (March 2026). Over 60 pending low-competition US launches target $400 million in revenue by FY28.
Strides Pharma Science firmographics
Firmographics- Name
- Strides Pharma Science
- Legal name
- Strides Pharma Science Limited
- Website
- https://strides.com
- Company type
- Public
- Founded year
- 1990
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- Strides Pharma Science is a publicly listed Indian pharmaceutical company that develops, manufactures, and commercializes IP-led generic formulations across 100+ countries, serving regulated markets, donor-funded public health programs, and African branded generics through seven global manufacturing facilities.
- Ownership category
- akta.pro rank
Strides Pharma Science industry classification
Industry- Product category
- Generic Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
- SIC
- Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Small-Molecule Generics (Branded/Unbranded) (HLAIABAA)
- akta.pro secondary industries
- Generic Hospital & Institutional Products (HLAIABAL), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)
Keywords
Where Strides Pharma Science is headquartered
LocationHeadquarters
- HQ city
- Bangalore
- HQ country
- India
- HQ region
- Asia
Offices16 records
Markets served
Strides Pharma Science business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Technology or R&D, Operations, Personnel, Marketing or Sales, Infrastructure
Revenue model
- Commercial Generic Pharmaceuticals: Sale of generic pharmaceutical products across regulated markets (US, Europe, Australia) and emerging markets (Africa, Asia Pacific, LATAM, MENA). Revenue generated through ANDAs, product launches, and market penetration. US market faces headwinds from weaker flu season and competition, while Ex-US markets contribute nearly 50% of revenue.
- Institutional/Public Health Business: Supply of essential medicines to donor-funded programs and international procurement agencies including Global Fund, USAID, UNICEF, PAHO, UNDP, PEPFAR. Products include WHO-prequalified formulations for HIV/AIDS, malaria, tuberculosis, and hepatitis treatments.
- Branded Generics (Africa): Sale of branded generic products in Africa through Brands Africa initiative. Products include Renerve, Combiart, Duotab, Vitafer, Unibrol for neuropathy, anaemia, malaria treatment. Operating in over 40 African countries with commercial field force.
- Contract Manufacturing (OneSource): OneSource Specialty Pharma (demerged and listed separately in January 2025) provides contract manufacturing services for GLP-1 and complex therapeutics. Projecting revenue growth from $170 million FY25 to $500 million by FY28 with 40% EBITDA margins.
Go-to-market motion3 records
Distribution channels7 records
Marketing channels7 records
Strides Pharma Science product offering
Product offeringCore offering
Strides Pharma Science develops, manufactures, and commercializes IP-led niche generic pharmaceuticals across diverse dosage forms including oral solids, modified-release formulations, topicals, nasal sprays, hormones, and controlled substances. The company operates through four integrated business models: (1) regulated-market generics in the US, Europe, Canada, Australia, and New Zealand; (2) institutional public health medicines for HIV/AIDS, malaria, tuberculosis, and hepatitis through donor-funded programs; (3) branded generics in 40+ African countries under the Brands Africa initiative; and (4) WHO-prequalified contract manufacturing through its Kenya-based Universal Corporation Limited (UCL) facility.
Product overview
Strides Pharma Science is a global pharmaceutical company specializing in the development and manufacturing of IP-led niche generics across diverse dosage forms including tablets, capsules, sachets, liquids, nasal sprays, topicals, and controlled substances. The company operates through multiple integrated business models: (1) a US-focused generics business with ANDAs and OTC products; (2) an institutional/public health medicines division supplying donor-funded programs for HIV/AIDS, malaria, and TB; (3) branded generics businesses in Africa (Brands Africa) and regulated markets (UK, DACH, Nordics); and (4) WHO-prequalified manufacturing through its Kenya-based Universal Corporation Limited facility. The portfolio spans anti-infectives, CNS, cardiovascular, gastroenterology, pain management, and specialty formulations.
Differentiator
Problem solved
Functional benefit
Brands
- Renerve: Brand for neuropathy treatment in Africa
- Combiart
- Duotab
- Vitafer
- Unibrol
Products and services
- Generic Pharmaceuticals Portfolio
- Institutional/Public Health Medicines
- Brands Africa - Branded Generics
- US Market Generic Pharmaceuticals
- Strides UK - Generic and OTC Medicines
- Strides Pharma International AG - DACH Region Portfolio
- Canada Generic Pharmaceuticals
- Universal Corporation Limited (UCL) - WHO-Prequalified Manufacturing
- Trinity Pharma Partnership - Southern Africa
- Nasal Spray Product Portfolio (OINDP)
Quantifiable outcome
- Ex-US markets contributed nearly 50% of Q4 FY26 revenue, demonstrating successful diversification strategy
- +4 more outcomes
Companies that use Strides Pharma Science
Customer profileNamed customers11 records
Segments6 records
Ideal customer profiles3 records
Strides Pharma Science technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Strides Pharma Science partnerships and signals
Strategic signalPartnerships
14 partnerships are on record, tiered core.
- Sandoz AGcoreStrides Pharma acquired Sandoz's portfolio of branded generic products for Sub-Saharan Africa for $12 million (approximately ₹111 crore). Portfolio includes anti-infective, cardiovascular, and dermatology products targeting Western Sahara, Ghana, Nigeria, and Kenya markets.
- Kenox Pharmaceuticals Inc.coreStrategic product development partnership to develop multiple nasal spray products for the US market across diverse therapeutic indications. Kenox provides formulation and development expertise in Orally Inhaled and Nasal Drug Products (OINDPs), combining with Strides' manufacturing and commercial strengths.
- Universal Corporation Limited (UCL)coreWHO-prequalified pharmaceutical manufacturer in Kenya serving as extended manufacturing arm for Strides under donor-funded contracts. Produces critical formulations including TLD (Tenofovir/Lamivudine/Dolutegravir) and Artemether/Lumefantrine for HIV/AIDS and malaria programs. Serves 30+ countries across Africa, Middle East, and donor markets.
- Trinity PharmacoreSouth Africa-based pharmaceutical partnership to serve private and public healthcare sectors in South Africa, Namibia, Botswana, and Lesotho. Broad therapeutic footprint spanning all major categories except oncology with deep regulatory expertise.
- Global FundcoreApproved supplier of WHO-prequalified formulations for HIV/AIDS, malaria, and tuberculosis through donor-funded programs serving disease-affected regions globally.
- USAIDcoreSupply of essential medicines to disease-affected regions through US government international development aid programs.
- UNICEFcoreEssential medicines supply for global child health programs and disease interventions through UNICEF procurement channels.
- Clinton Health Access InitiativecoreStrategic collaboration expanding access to essential medicines and treatments in low and middle-income countries through program support and market-shaping initiatives.
- Medicines Patent PoolcoreCollaboration through licensing and voluntary pool mechanisms to expand access to patented medicines in developing countries.
- Medicines for Malaria VenturecoreProduct development partnerships for malaria treatments, contributing to global malaria control efforts through affordable, quality-assured medicines.
- ViiV HealthcarecoreLicensing partnerships for HIV/AIDS treatments including dolutegravir-based formulations. Supported by technology transfer and manufacturing capabilities.
- Gilead SciencescoreAntiviral treatments collaboration through licensing, technology transfer, and supply arrangements for hepatitis and HIV treatments.
- PAHOcoreEssential medicines supply across Latin American and Caribbean regions through PAHO's regional procurement mechanisms.
- UNITAIDcoreHIV/AIDS, hepatitis, and tuberculosis treatments supply through international procurement agency for underserved markets.
Scale indicators17 records
Recent moves9 records
Expansion highlights5 records
Strides Pharma Science competitors and assessment
Company assessmentDirect peers
- Lupin: Indian generic pharma with US ANDA focus and complex generics capabilities. Direct peer across regulated-market strategy, manufacturing footprint, and emerging-markets push.
- Zydus Lifesciences: Indian pharmaceutical company with US generics, biosimilars, and a wide emerging-markets presence. Comparable in scale, geographic mix, and pipeline depth.
- Glenmark Pharmaceuticals: Indian pharma with branded generics, complex generics, and specialty/API exposure. Overlaps with Strides in niche generics strategy and emerging-markets commercial model.
- Cipla: Indian pharma major with strong presence in HIV/AIDS, respiratory, and institutional/global health segments. Highly comparable in the donor-funded institutional franchise and Africa footprint.
- Aurobindo Pharma: Indian generic major with a similarly large US ANDA portfolio, multiple manufacturing facilities, and significant emerging-markets exposure. Closely comparable business model spanning regulated and emerging markets.
- Dr. Reddy's Laboratories: Indian generic pharmaceutical company with parallel US ANDA pipeline, complex generics focus, and emerging-markets operations. Direct competitor across oral solids, injectables, and biosimilars.
- Alembic Pharmaceuticals: Indian generic pharma with US ANDA focus, India branded business, and international operations. Comparable in size, pipeline orientation, and emerging-market ambitions.
Broad incumbents
- Sun Pharmaceutical Industries: Largest Indian pharma company with a much broader specialty and generics portfolio including branded US. Larger and more diversified, but the closest reference point for Strides' market positioning.
- Viatris: Global generics and biosimilars major with deep institutional/global-health channel and a broad off-patent portfolio. Reference peer for the international institutional and Africa segments where Strides competes.
Emerging players
- Natco Pharma: Indian pharma focused on complex generics and oncology with strong US niche-ANDA strategy. Comparable in IP-led differentiation and focus on limited-competition launches.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Strides Pharma Science social profiles
Digital presenceStrides Pharma Science compliance and trust
Trust signalCompliance11 records
Strides Pharma Science financial estimates
Financial estimateRevenue estimate
Valuation estimate
Strides Pharma Science leadership team
Management profileNumber of profiles
Profiles11 records
Strides Pharma Science subsidiaries and ownership
Company hierarchySubsidiaries14 records
Strides Pharma Science funding detail
Funding detailFunding overview
Funding rounds3 records
Investors4 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Strides Pharma Science M&A and investment
M&A and investmentM&A5 records
Investments3 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Strides Pharma Science
What does Strides Pharma Science do?
Strides Pharma Science develops, manufactures, and commercializes IP-led niche generic pharmaceuticals across diverse dosage forms including oral solids, modified-release formulations, topicals, nasal sprays, hormones, and controlled substances. The company operates through four integrated business models: (1) regulated-market generics in the US, Europe, Canada, Australia, and New Zealand; (2) institutional public health medicines for HIV/AIDS, malaria, tuberculosis, and hepatitis through donor-funded programs; (3) branded generics in 40+ African countries under the Brands Africa initiative; and (4) WHO-prequalified contract manufacturing through its Kenya-based Universal Corporation Limited (UCL) facility.
Is Strides Pharma Science a public or private company?
Strides Pharma Science is a public company. It is classified as public and is currently operating.
When was Strides Pharma Science founded?
Strides Pharma Science was founded in 1990. It employs 1,001 to 5,000 people.
Where is Strides Pharma Science based?
Strides Pharma Science is headquartered in Bangalore, India, in the Asia region.
How does Strides Pharma Science make money?
Four revenue lines are on record. Commercial Generic Pharmaceuticals are the primary driver. The others are institutional/Public Health Business, branded Generics (Africa) and contract Manufacturing (OneSource).
Who are Strides Pharma Science's main competitors?
Direct peers on record are Lupin, Zydus Lifesciences, Glenmark Pharmaceuticals, Cipla, Aurobindo Pharma, Dr. Reddy's Laboratories and Alembic Pharmaceuticals. Broad incumbents are Sun Pharmaceutical Industries and Viatris. Natco Pharma is listed as an emerging player.
Does Strides Pharma Science have an API?
No public API is recorded for Strides Pharma Science.
What industry is Strides Pharma Science in?
Strides Pharma Science's product category is Generic Pharmaceuticals. Its primary akta.pro industry code is HLAIABAA, Small-Molecule Generics (Branded/Unbranded), with a secondary code of HLAIABAL, Generic Hospital & Institutional Products. Its NAICS code is 325412 and its SIC code is 2834.